Ibrance Dosages: I Need Your Feedback

I've been on it about a year at 125. Each month seems to bring a different se, but then goes away. Except for the constant low grade nausea. I can't eat, don't want to eat. Not vomiting. Just yucky. On week off, all good.

MO says my counts are always low, but he's not concerned. So when I see him next, I'll mention the nausea, he may drop it. We'll see.

Some on ibrance are on 75 and doing well too.

Check out the ibrance thread too.

I reduced from 125 to 100 after a couple cycles because of mouth sores. I was on 100 for quite a while, then went to 75 because of fatigue. I got my two years out of it. I did the usual schedule. I am a person who typically needs a lower-than-average dose of anything.

I did worry that going to 75 shortened the time the drugs were effective, but my genomic testing revealed that a mutation had developed that would cause resistance.

Hello Tina I have been on Ibrance & Letrozole for almost 4 years. I requested to drop down to 100mg a few months in although my bloods were mainly ok. The 3 Onc’s involved in my case at the time all agreed that this should really be the starting dose for most people. I strongly feel that weight, age etc etc have an influence on the dosage and dosing of these meds. In other words a high enough dose to work but not to floor us and cause us to keep taking breaks. Good luck to you & I do hope that Ibrance works for you. It has se’s but I really don’t want to change to anything else - except one day to immunotherapy 🤞

You're "talking the Patient-Centered Dosing Initiative's language!"

The PCDI believes that patients and their physicians should discuss available dosing options (except for endocrine therapies, which have only 1 dose) when patients start a new drug or have treatment-related side effects on the starting (maximum tolerated) dose.

Here are some studies regarding Ibrance:

A Phase II study that randomized 72 HR+ HER2- MBC patients to receive Ibrance in either a 125 mg or 100 mg dose in combination with physician's choice of fulvestrant or tamoxifen concluded that the 100 mg dose was associated with a lower rate of grade 3 or 4 neutropenia. Furthermore, both Progression Free Survival and clinical benefit were the same in both groups. Dr Hope Rugo was the lead investigator. https://www.targetedonc.com/news/reduced-palbociclib-dose-associated-with-lower-rate-of-neutropenia-in-hr-metastatic-breast-cancer

In a slide entitled, "PALOMA-3: Effect on PFS of Dose Reductions due to Neutropenia" presented by Dr. Sara Hurvitz at Clinical Care Options Oncology on June 18, 2020, it was reported that the PFS observed between patients who had ≥ 1 Ibrance dose reduction vs. no dose reduction due to neutropenia was identical at 9.5 months.